Log in

Titan Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/17/2020 12:00 AM ET)
Today's Range
Now: $0.20
50-Day Range
MA: $0.25
52-Week Range
Now: $0.20
Volume2.11 million shs
Average Volume12.21 million shs
Market Capitalization$19.72 million
P/E RatioN/A
Dividend YieldN/A
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:TTNP



Sales & Book Value

Annual Sales$3.61 million
Book Value$0.02 per share


Net Income$-16,460,000.00
Net Margins-351.69%


Market Cap$19.72 million
Next Earnings Date11/12/2020 (Estimated)
0.00 (0.00 %)
(As of 09/17/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TTNP News and Ratings via Email

Sign-up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions

How has Titan Pharmaceuticals' stock price been impacted by COVID-19?

Titan Pharmaceuticals' stock was trading at $0.2445 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TTNP shares have decreased by 17.1% and is now trading at $0.2028.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Titan Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Titan Pharmaceuticals

When is Titan Pharmaceuticals' next earnings date?

Titan Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Titan Pharmaceuticals

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its quarterly earnings data on Friday, August, 14th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.02. The specialty pharmaceutical company earned $1.33 million during the quarter, compared to analysts' expectations of $1.60 million. Titan Pharmaceuticals had a negative return on equity of 1,144.30% and a negative net margin of 351.69%.
View Titan Pharmaceuticals' earnings history

When did Titan Pharmaceuticals' stock split? How did Titan Pharmaceuticals' stock split work?

Shares of Titan Pharmaceuticals reverse split on Friday, January 25th 2019. The 1-6 reverse split was announced on Thursday, January 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 24th 2019. An investor that had 100 shares of Titan Pharmaceuticals stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for TTNP?

1 equities research analysts have issued 12-month target prices for Titan Pharmaceuticals' shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Titan Pharmaceuticals' share price to reach $1.00 in the next twelve months. This suggests a possible upside of 393.1% from the stock's current price.
View analysts' price targets for Titan Pharmaceuticals

Who are some of Titan Pharmaceuticals' key competitors?

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include BioNano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Novan (NOVN), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), AEterna Zentaris (AEZS), Cannabics Pharmaceuticals (CNBX) and Pennsylvania R.E.I.T. (PEI).

Who are Titan Pharmaceuticals' key executives?

Titan Pharmaceuticals' management team includes the following people:
  • Dr. Marc Rubin, Exec. Chairman (Age 64)
  • Mr. Sunil Bhonsle, Pres, CEO, Principal Financial Officer & Director (Age 69)
  • Dr. Katherine L. Beebe-DeVarney Ph.D., Exec. VP & Chief Scientific Officer (Age 58)
  • Mr. Dane D. Hallberg, Exec. VP & Chief Commercial Officer (Age 50)

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

Who are Titan Pharmaceuticals' major shareholders?

Titan Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Private Advisor Group LLC (0.22%), Virtu Financial LLC (0.15%) and UBS Group AG (0.12%). Company insiders that own Titan Pharmaceuticals stock include James R Mcnab, Marc Rubin and Sunil Bhonsle.
View institutional ownership trends for Titan Pharmaceuticals

Which major investors are buying Titan Pharmaceuticals stock?

TTNP stock was purchased by a variety of institutional investors in the last quarter, including Private Advisor Group LLC, Virtu Financial LLC, and UBS Group AG. Company insiders that have bought Titan Pharmaceuticals stock in the last two years include James R Mcnab, Marc Rubin, and Sunil Bhonsle.
View insider buying and selling activity for Titan Pharmaceuticals

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Titan Pharmaceuticals' stock price today?

One share of TTNP stock can currently be purchased for approximately $0.20.

How big of a company is Titan Pharmaceuticals?

Titan Pharmaceuticals has a market capitalization of $19.72 million and generates $3.61 million in revenue each year. The specialty pharmaceutical company earns $-16,460,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Titan Pharmaceuticals employs 23 workers across the globe.

What is Titan Pharmaceuticals' official website?

The official website for Titan Pharmaceuticals is www.titanpharm.com.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.